| Co-Investigator(Kenkyū-buntansha) |
KISHIKAWA Michiko (KIYAMA Michiko) Nihon University, School of Dentistry at Matsudo, Resarch Assistant (Full-Time), 松戸歯学部, 助手 (50256905)
SHIBATA Yasuko Nihon University, School of Dentistry at Matsudo, Lecturer (Full-Time), 松戸歯学部, 講師 (90133438)
SAITO Shigeno Nihon University, School of Dentistry at Matsudo, Lecturer (Full-Time), 松戸歯学部, 講師 (60072394)
|
|---|
| Research Abstract |
The passive immunotherapy is a method for neutralizing the pathogenicity using antibody against each pathogen. Recently, it has been suggested that periodontal diseases are one of the consequential risk factors for several systemic diseases. As one of the medical treatments for the maintenance for human health, the development of passive immunotherapy for periodontal disease may be significant and necessary. Following research idea to construct the human monoclonal. antibodies (HmAbs) for the safety passive immunotherapy were carried out: Because the molecular information of the target antigens were important to use the HmAbs for passive immunotherapy, preliminary we attempted to clarify the molecule functional analysis of target antigens, such as hemagglutinin molecules and coaggregation factor of Porphyromonas gingivalis, and glucosyltransferases (GTFs) of Streptococcus sobrinus. Additionally, the large volume purification system by osmotic electrophoresis was also improved.
The HmAbs
… More
for passive immunity examined 1) the human lymphocyte immortalization method using EB virus, 2) the method, using Xenomouse, 3) the method using Transchromomouse, and hmAbs were produced using these methods. In addition, recombinant ScFv using mouse monoclonal antibody producing hybridoma cell was improved into the large-scale production system, moreover, IgY antibody by the chicken immunity was also produced. In this study, the, practicable abilities of clones were screening using a Biacore system to detect the mAbs levels and avidity in cultured medium. The constructed HmAbs ability was determined the neutralization levels against the pathogenicity of antigens.
Using Xenomouse technology, we succeeded to construct the HmAbs against the hemagglutinin of P. gingivalis, and GTFs of 」 sobrinus., Moreover, using Transchromomouse technology, HmAb against the coaggregation factor of P gingivalis was also constructed. Interestingly, the anti-coaggregation factor antibodies could increase the neutrophilic activity to phagocytize the P gingivlais cells. We also succeeded in the construction of IgY antibody against the hemagglutinin activity of P gingivalis. Less
|
